Management of the New Patient with CML in Chronic Phase
- First Online:
- Cite this article as:
- Marin, D. Curr Hematol Malig Rep (2013) 8: 37. doi:10.1007/s11899-012-0151-0
Imatinib has been the preferred initial therapy for newly diagnosed chronic myeloid leukemia (CML) patients for the last 10 years. Today, other tyrosine kinase inhibitors (TKIs) are licensed for first-line use. In this paper we analyze the pros and cons of the various alternatives to imatinib and try to give some advice on the management of the newly diagnosed patient.